logo
Lincoln Electric Holdings, Inc. (LECO): One of the Overlooked Dividend Stocks to Buy Now

Lincoln Electric Holdings, Inc. (LECO): One of the Overlooked Dividend Stocks to Buy Now

Yahoo26-04-2025
We recently published a list of the 10 Overlooked Dividend Stocks to Buy Now. In this article, we are going to take a look at where Lincoln Electric Holdings, Inc. (NASDAQ:LECO) stands against other overlooked dividend stocks.
In recent times, dividend investing—also known as equity income—has fallen out of favor. Once a widely followed and dependable strategy, it has gradually been overshadowed. The strong capital gains delivered by growth stocks appear to have shifted investors' attention away from the more stable and consistent returns that come with dividend-paying stocks.
However, the recent market downturn, combined with the economic impact of Trump's trade policies, has brought renewed attention and appeal to these types of stocks. The S&P Dividend Aristocrats Index, which tracks the performance of companies with at least 25 consecutive years of dividend growth, has fallen by a little over 2% since the start of 2025, compared with a 6% fall in the broader market.
Dividend stocks have seen mixed results over different economic cycles—performing well in some downturns and falling behind in others. They generally outpaced the broader market during the recessions starting in July 1981, March 2001, and December 2007. However, their performance lagged during the shorter recessions in 1980 and 2020. This was mainly due to dividend cuts from major firms, along with limited exposure to fast-growing tech names. For context, the steepest drop in dividends came during the 2008–09 financial crisis, when S&P dividend payouts declined by 24%, though investors still received 76% of their income.
That said, while the possibility of dividend reductions is a valid concern and a potential drawback of this strategy, it shouldn't be a reason to overlook dividend stocks altogether. When incorporated thoughtfully, they can still play a valuable role in a well-rounded investment portfolio.
M&G Investments noted that dividends serve as more than just income—they also signal a company's financial health and management's confidence. While short-term market returns often hinge on stock valuations, dividends play a much more substantial role in driving equity returns over longer periods, such as 10 or 20 years. The report also mentioned, citing Bloomberg's data, that dividends play a vital role in long-term returns. Over the last 25 years, nearly half of the total gains from US stocks have come from reinvested dividends and the power of compounding. During this period, the broader market delivered an average annual return of 7.4%, with 55% attributed to rising stock prices and the remaining 45% coming from reinvested dividend income.
The fact that dividends are not guaranteed highlights a deeper financial story behind corporate decisions. Companies must carefully weigh the trade-off between returning profits to shareholders and keeping enough earnings on hand to support future expansion. Getting this balance right is a strategic task.
A particularly high dividend payout ratio—typically above 75%, though this varies by sector—can raise red flags about sustainability. When too much profit is paid out, there's little room left to increase dividends down the line. This could eventually lead a company to scale back or even stop its dividend payments altogether, which may hold back both business growth and long-term gains in share value. Given this, we will take a look at some overlooked stocks that pay dividends.
A welder wearing protective gear, wearing a satisfied expression after completing his work.
For this list, we thoroughly reviewed reputable sources such as Forbes, Morningstar, Barron's, and Business Insider and searched for stocks that remain under the radar but have strong balance sheets and sound financials. In addition, these lesser-known dividend companies also boast dividend growth track records, which make them a reliable option for income investors. After compiling our data, we picked 10 companies with the highest number of hedge fund investors, as per Insider Monkey's Q4 2024 database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
Number of Hedge Fund Holders: 36
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) is an Ohio-based multinational company that specializes in welding products. The company is also known for its proficiency in industrial automation and cutting equipment. Recently, the company has focused on expanding its industrial automation segment, anticipating significant growth and nearly $1 billion in revenue.
Lincoln Electric Holdings, Inc. (NASDAQ:LECO)'s strategy revolves around meeting customer demand and effectively managing costs. By delivering high-quality products and fostering strong brand loyalty, the company maintains a competitive edge in a mature industry. Its investment in technology and commitment to a skilled workforce further strengthen its market position.
In the fourth quarter of 2024, Lincoln Electric Holdings, Inc. (NASDAQ:LECO) reported revenue of $1.02 billion, down 3.45% from the same period last year. However, the revenue surpassed analysts' estimates by over $26 million. Although enhanced operational efficiencies had a positive impact, macroeconomic challenges and fluctuations in industrial sector demand continued to pose potential risks. Special item charges and higher selling expenses led to a 10.5% year-over-year decline in net income, which totaled $140.2 million.
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) ended the year with over $377 million in cash and cash equivalents. The company reported an operating cash flow of $95.8 million. In FY24, it returned $426 million to shareholders through dividends and share repurchases, affirming its commitment to shareholder return. In addition, it has been growing its payouts for 29 consecutive years. Currently, it pays a quarterly dividend of $0.75 per share for a dividend yield of 1.61%, as of April 25.
Overall, LECO ranks 3rd on our list of the best overlooked dividend stocks to invest in. While we acknowledge the potential of LECO as an investment, our conviction lies in the belief that some deeply undervalued dividend stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued dividend stock that is more promising than LECO but that trades at 10 times its earnings and grows its earnings at double digit rates annually, check out our report about the .
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at .
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CNBC Daily Open: Despite cooler-than-expected CPI, economists agree higher prices are coming
CNBC Daily Open: Despite cooler-than-expected CPI, economists agree higher prices are coming

CNBC

time9 minutes ago

  • CNBC

CNBC Daily Open: Despite cooler-than-expected CPI, economists agree higher prices are coming

Don't mess with DJ D-Sol — Goldman Sachs CEO David Solomon's stage name when he's rocking the clubs in his other life as a DJ. U.S. President Donald Trump criticized Goldman on Tuesday for predicting that tariffs would push up inflation, and said Solomon "should go out and get himself a new Economist or, maybe, he ought to just focus on being a DJ." In response, Goldman defended the results of its study, according to a CNBC interview with the bank's economist David Mericle. "If the most recent tariffs, like the April tariff, follow the same pattern that we've seen with those earliest February tariffs, then eventually, by the fall, we estimate that consumers would bear about two-thirds of the cost," Mericle said. Goldman, in fact, is not the only Wall Street bank putting forth this view. UBS senior economist Brian Rose wrote that "the downward trend in core inflation has been broken as tariffs start to feed through into retail prices," while Michael Feroli, chief U.S. economist at JPMorgan Chase, said in a note that tariffs could "add 1-1.5% to inflation, some of which has already occurred." Of course, a consensus view does not mean predictions will come true. Recall how economists were all but certain a U.S. recession would happen in 2023 — only for the economy to grow 2.5% that year. In any case, if Goldman — and economists from other banks —is proven wrong on tariff-driven inflation, and Trump, in a hypothetical scenario, manages to somehow push Solomon out of his position, at least DJ D-Sol will still be out there spinning is considering 11 candidates for Fed chair. Among the list of potential nominees are Federal Reserve officials, a Bush administration economic advisor, Jefferies Chief Market Strategist David Zervos and BlackRock's Rick Rieder. Economists agree that higher tariff inflation is coming. Despite Trump on Tuesday slamming Goldman Sachs for predicting higher consumer prices, the bank is standing by its research. Other Wall Street economists agree with its call. New records for U.S. stocks again. The S&P 500 and Nasdaq Composite climbed Tuesday to close at fresh highs, with the Dow Jones Industrial Average also rising. Shares of Paramount Skydance popped 36.7%. The Stoxx Europe 600 added 0.54%. xAI's co-founder Igor Babuschkin leaves. Babuschkin said he's starting a venture firm to support AI safety research and invest in startups. Musk wrote, in response, "Thanks for helping build @xAI! We wouldn't be here without you." [PRO] This software stock could jump 50%, Morgan Stanley says. The firm's shares tumbled Monday because of lackluster third-quarter guidance — but that move created "the entry point for which we've been waiting," a Morgan Stanley analyst wrote. How Big Tech is paying its way out of Trump's tariffs Top tech executives are at the forefront of a recent swathe of unprecedented deals with U.S. President Donald Trump. In particular, Nvidia and Advanced Micro Devices, as well as Apple, have struck agreements with the White House. "The flurry of deal-making is an effort to secure lighter treatment from tariffs," Paolo Pescatore, technology analyst at PP Foresight, told CNBC by email. Big tech companies can "ill afford to fork out on millions of dollars in additional fees that will further dent profits as underlined by recent quarterly earnings," Pescatore said.

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Yahoo

time11 minutes ago

  • Yahoo

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabled by AI-driven AP3 Generative Phosphoproteomics platform Cash, cash equivalents and marketable securities of $147.6 million as of June 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. 'The strength of the clinical data across our two clinical assets speaks to the expanding capabilities of our AP3 platform to enable pathway-based drug design and optimized drug development by delivering actionable insights,' said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. 'With ACR-368, we have seen deep and durable responses in patients with various types of aggressive endometrial cancer who had all progressed on prior chemotherapy and anti-PD1 therapy – a high unmet need population. Based on our clinical data, and the AP3-discovered insight that ultra low-dose gemcitabine sensitizes tumors to ACR-368 treatment, we believe there is an opportunity to further expand the patient population benefiting from ACR-368 by treating all-comer, biomarker-unselected 2nd line patients, who have all received prior chemotherapy and anti-PD-1, with ACR-368 and ultra low-dose gemcitabine. Our fully internally developed second clinical-stage asset, ACR-2316, which is being advanced in a Phase 1 trial, has demonstrated initial clinical activity during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer, signaling the broad potential of this agent.' Recent Highlights ACR-368: CHK1 and CHK2 Inhibitor Continued advancement of the ongoing registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with recurrent high-grade endometrial cancer who have all received prior platinum-based chemotherapy and prior immune checkpoint inhibitor treatment regimens Initiated a third arm to the Phase 2b study without the need for a pre-treatment biopsy to evaluate ACR-368 with ultra low-dose gemcitabine (ULDG) as a tumor sensitizer in all-comer, biomarker-unselected 2nd line patients with endometrial cancer who have all received prior treatment with chemotherapy and anti-PD-1 ACR-2316: WEE1/PKMYT1 Inhibitor Continued enrolling patients in the Phase 1 monotherapy dose-escalation trial for certain high unmet need solid tumor types prioritized based on AP3-predicted sensitivity to ACR-2316 No dose-limiting toxicities observed in three cleared dose levels Evidence of drug target engagement observed as early as dose level 1 Initial clinical activity observed during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer Generative Phosphoproteomics AP3 Platform At the AACR Annual Meeting in April 2025, presented Generative Phosphoproteomic AP3 analyses uncovering key molecular mechanisms by which ACR-2316 induces strong mitotic, pro-apoptotic tumor cell death believed to be critical for its potent, preclinical single-agent activity Anticipated Upcoming Milestones Provide update on registrational-intent trial and confirmatory trial design for ACR-368 in the second half of 2025 Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025 Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025 Second Quarter 2025 Financial Results Net loss for the quarter ended June 30, 2025 was $21.0 million compared to a net loss of $18.8 million for the same period in 2024. Research and development expenses were $16.2 million for the quarter ended June 30, 2025 compared to $15.0 million for the same period in 2024. The difference was primarily due to increased personnel to support the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement. General and administrative expenses were $6.5 million for the quarter ended June 30, 2025, which is materially consistent with $6.4 million for the same period in 2024. As of June 30, 2025, the company had cash, cash equivalents and investments of $147.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development. Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law. Investor and Media Contacts: Adam D. Levy, Ph.D., Alexandra Santos asantos@ Acrivon Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited, in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 16,182 $ 15,025 $ 31,596 $ 26,498 General and administrative 6,467 6,412 12,715 12,607 Total operating expenses 22,649 21,437 44,311 39,105 Loss from operations (22,649 ) (21,437 ) (44,311 ) (39,105 ) Other income (expense), net: Interest income 1,730 2,694 3,726 4,140 Other expense, net (87 ) (55 ) (101 ) (319 ) Total other income, net 1,643 2,639 3,625 3,821 Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Net loss per share - basic and diluted $ (0.55 ) $ (0.52 ) $ (1.06 ) $ (1.20 ) Weighted-average common stock outstanding - basic and diluted 38,461,619 36,132,616 38,406,339 29,361,710 Comprehensive loss: Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Other comprehensive income (loss): Unrealized (loss) gain on available-for-sale investments, net of tax (177 ) 51 (341 ) 64 Comprehensive loss $ (21,183 ) $ (18,747 ) $ (41,027 ) $ (35,220 ) Acrivon Therapeutics, Inc. Condensed Consolidated Balance Sheets (unaudited, in thousands) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 41,895 $ 39,818 Investments 105,727 144,751 Other assets 10,961 12,019 Total assets $ 158,583 $ 196,588 Liabilities and Stockholders' Equity Liabilities $ 15,546 $ 19,802 Stockholders' Equity 143,037 176,786 Total Liabilities and Stockholders' Equity $ 158,583 $ 196,588 Sign in to access your portfolio

Apple (AAPL) Upgrading Siri with AI-Powered Apple Intent
Apple (AAPL) Upgrading Siri with AI-Powered Apple Intent

Yahoo

time12 minutes ago

  • Yahoo

Apple (AAPL) Upgrading Siri with AI-Powered Apple Intent

Apple Inc. (NASDAQ:AAPL) is one of the tech stocks with strong return on equity. On August 10, it was announced that the company is working on a significant upgrade to its AI voice control, which will change how people use iPhones. Reports indicate that the company is working on an upgraded version of App Intents that will make Siri the true hands-free controller for devices. App Intents will enable people to use their voice to instruct Siri to perform complex operations, such as finding a specific photo, editing it, and sending it off. Thanks to artificial intelligence integration, the digital assistant can comment on an Instagram photo or scroll through a shopping app and add items to a cart. With the new upgrades, Apple is exploring ways to make its voice control operate with precision inside interfaces. The upgrades would mark an important milestone and fulfillment of a promise that Siri made 15 years ago. It will also be a significant upgrade to the company's hardware. Without App Intents, Apple's products would be less compelling than those offered by Amazon and Google. Apple Inc. (NASDAQ:AAPL) is a technology company that designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories. It also sells a variety of related services, including software, digital content, and subscription-based services. The stock boasts of a high return on equity of 149.81%, affirming its ability to convert shareholder equity to profit. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best NYSE Penny Stocks to Invest in Now and 10 Best 52-Week High Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store